Development of orally disintegrating tablets of Perphenazine/hydroxypropyl- β-cyclodextrin inclusion complex

Pharmaceutical Development and Technology

Volumn 18, Issue 5, 2013, Pages 1101-1110

  Wang, Ling ^a   Zeng, Fan ^a   Zong, Li ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Dissolution rate; Hydroxypropyl cyclodextrin; Inclusion complex; Orally disintegrating tablets; Perphenazine

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CROSCARMELLOSE SODIUM; CROSPOVIDONE; MAGNESIUM STEARATE; MANNITOL; PERPHENAZINE;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; SOLID STATE; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET MANUFACTURE; TABLET POROSITY; THICKNESS; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HARDNESS; PERPHENAZINE; POROSITY; SOLUBILITY; TABLETS;

EID: 84885437682     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.700932     Document Type: Article

References (31)

1. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ter Drug Carrier Syst 2004;21:433-476.
2. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul 2008;2:258-274.
3. Sweetman SC. (2009). Martindale: The complete drug reference. 36th edition. London: Pharmaceutical Press, 1017.
4. Laitinen R, Suihko E, Toukola K, Björkqvist M, Riikonen J, Lehto VP et al. Intraorally fast-dissolving particles of a poorly soluble drug: preparation and in vitro characterization. Eur J Pharm Biopharm 2009;71:271-281.
5. Lindenberg M, Kopp S, Dressman JB. Classifcation of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classifcation system. Eur J Pharm Biopharm 2004;58:265-278.
6. Wang S, Ding Y, Yao Y. Inclusion complexes of fuorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm 2009;35:808-813.
7. Klein S, Wempe MF, Zoeller T, Buchanan NL, Lambert JL, Ramsey MG et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-beta-cyclodextrin. J Pharm Pharmacol 2009;61:23-30.
8. Parmar KR, Patel KA, Shah SR, Sheth NR. Inclusion complexes of lamotrigine and hydroxyl propyl β-cyclodextrin: solid state characterization and dissolution studies. J Incl Phenom Macrocycl Chem 2009;65:263-268.
9. Ranpise NS, Kulkarni NS, Mair PD, Ranade AN. Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Pharm Dev Technol 2010;15:64-70.
10. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004;272:1-10.
11. Laitinen R, Suihko E, Bjorkqvist M, Riikonen J, Lehto VP, Jarvinen K et al. Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm 2010;36:601-613.
12. Turunen E, Mannila J, Laitinen R, Riikonen J, Lehto VP, Järvinen T et al. Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. J Pharm Pharmacol 2011;63:19-25.
13. Cappello B, di Maio C, Iervolino M, Miro A, Calignano A. Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies. Drug Dev Ind Pharm 2009;35:877-886.
14. Veiga F, Fernandes C, Teixeira F. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm 2000;202:165-171.
15. Zeng J, Ren Y, Zhou CL, Yu SQ, Chen WH. Preparation and physicochemical characteristics of the complex of edaravone with hydroxypropyl-β- cyclodextrin. Carbohyd Polym 2011;83:1101-1105.
16. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum 1965;4:117-212.
17. Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and nondestructive methods of evaluation. Int J Pharm 2010;400:49-58.
18. Abdelbary A, Elshafeey AH, Zidan G. Comparative effects of diferent cellulosic-based directly compressed orodispersable tablets on bioavailability of famotidine. Carbohyd Polym 2009;77:799-806.
19. Rajitha K, Shravan KY, Adukondalu D, Ramesh G, Madhusudan Y. Formulation and Evaluation of Orally Disintegrating Tablets of Buspirone. Int J Pharm Sci and Nanotechnol 2009;1:372-374.
20. Fernandes CM, Teresa Vieira M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 2002;15:79-88.
21. Aki H, Niiya T, Iwase Y, Kawasaki Y, Kumai K, Kimura T. Multimodal inclusion complexes of ampicillin with β-cyclodextrins in aqueous solution. Termochim Acta 2004;416:87-92.
22. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007;123:78-99.
23. Figueiras A, Carvalho RA, Ribeiro L, Torres-Labandeira JJ, Veiga FJ. Solid-state characterization and dissolution profles of the inclusion complexes of omeprazole with native and chemically modifed beta-cyclodextrin. Eur J Pharm Biopharm 2007;67:531-539.
24. Phillip Lee YH, Sathigari S, Jean Lin YJ, Ravis WR, Chadha G, Parsons DL et al. Geftinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm 2009;35:1113-1120.
25. Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafl with natural and chemically modifed beta-cyclodextrins. I: preparation and in-vitro evaluation. Eur J Pharm Biopharm 2008;70:819-827.
26. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS et al. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2007;66:413-421.
27. Lutka A, Prange W. Comparison of the effect of the R2 phenothiazine ring substituent on fuphenazine and perphenazine interactions with cyclodextrins. Acta Pol Pharm 2005;62:419-425.
28. Sheshala R, Khan N, Darwis Y. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate. Chem Pharm Bull 2011;59:920-928.
29. Abed KK, Hussein AA, Ghareeb MM, Abdulrasool AA. Formulation and optimization of orodispersible tablets of diazepam. AAPS PharmSciTech 2010;11:356-361.
30. Jeong SH, Lee J, Woo JS. (2010). Fast disintegrating tablets. In: Wen H, Park K, ed. Oral controlled release formulation design and drug delivery: theory to practice. New Jersey: John Wiley & Sons, Inc., 155-167.
31. Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003;20:327-334.